ArticlePolymer engineering and science2022
Antiviral capacity of polypropylene/(1-Hexadecyl) trimethyl-ammonium bromide composites against COVID-19.
Article in Polymer engineering and science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 10 citations in OpenAlex.
- Antiviral activity of natural and modified hydrocolloids: main sources, susceptible viruses, structure-activity relationship and mechanisms of action.Frontiers in nutrition · 2025Review
- Antiviral efficacy of nanomaterial-treated textiles in real-life like exposure conditions.Heliyon · 2023Article
- Antiviral capacity of polypropylene/(1-Hexadecyl) trimethyl-ammonium bromide composites against COVID-19.Polymer engineering and science · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
During the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, scientists from different areas are looking for alternatives to fight it. SARS-CoV-2, the cause of the infectious respiratory disease COVID-19, is mainly transmitted through direct or indirect contact with infected respiratory droplets. The integrity of the virus structure is crucial for its viability to attack human cells. Quaternary ammonium salts are characterized by having antiviral capabilities which alter or destroy the structure of the viral capsid. In this work, polypropylene (PP)/(1-Hexadecyl) trimethyl-ammonium bromide (CTAB) composites have been prepared in order to create an antiviral material. The composites were melt processed and blown to produce thin films. The CTAB content on the antiviral effect was evaluated using antibodies and serum from infected patients with the SARS-CoV-2 virus. In addition, the mechanical and thermal properties of blown films were investigated, and CTAB release kinetics from the films was followed by UV-Vis. The results indicate that the virus tends to remain less on the polymer surface by increasing the amount of CTAB in the PP matrix.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.